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Abstract
Background: An increasing number of patients have been described as having a number of Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) variants for which it lacks a clear genotype–phenotype correlation.
We assesses the clinical features of patients bearing the S737F (p.Ser737Phe) CFTR missense variant and evaluated
the residual function of CFTR protein on nasal epithelial cells (NEC).
Methods: A retrospective database was performed from individuals homozygous or compound heterozygous for
the S737F variant followed in the Cystic Fibrosis (CF) Centre of Florence. We performed a nasal brushing in cooperating
patients and compared the results with those of patients followed in the pediatric CF Centre of Naples.
Results: 9/295 (3%) subjects carrying at least S737F CFTR variant on one allele were identified. Patients were diagnosed
in 7/9 cases by newborn screening and in two cases for dehydration with hypochloremic metabolic alkalosis; at
diagnosis sweat chloride levels (SCL) were in the pathological range in only one case. After a mean follow up of
8,6 years (range 0,5–15,8), SCL were in the pathological range in 8/9 cases (mean age at CF diagnosis: 1,5 years),
all patients were pancreatic sufficiency and respiratory function was normal. The gating activity on NEC was 15.
6% and 12.7% in two patients compound heterozygous for W1282X and DelE22_24, while it was ranged between
6,2% and 9,8% in CF patients.
Conclusions: S737F is a CFTR mutation associated to hypochloremic alkalosis in childhood, mild CF phenotype in
teenage years and a residual function of CFTR protein.
Keywords: Cystic fibrosis, CFTR, Nasal brushing, Functional analysis, Gating, Genotype-phenotype correlation,
Tuscany region, CFSPID, CRMS
Background
Cystic fibrosis (CF) is the most common life-threatening
autosomal recessive disease in the US, affecting approxi-
mately 1 in 4000 newborns [1]. The prevalence in
Europe is 0.737 per 10,000 and the incidence in Italy is
estimated at 1/4,238 live [2]. It is caused by mutations of
the CF Transmembrane conductance Regulator gene
(CFTR) that encodes the cAMP-regulated chloride chan-
nel. About 2000 variants were described in the CFTR
gene so far [3]. CFTR mutations can be classified into 6
classes according to the mechanism by which they
impair CFTR protein synthesis, trafficking or function:
class I mutations cause absent CFTR production, class II
mutations affect intracellular processing of CFTR and
class III mutations lead to defective regulation of the
CFTR channel at the apical plasma membrane; classes
IV, V and VI are associated to some degree of residual
function [3, 4].
Although CFTR functions mainly as a chloride
channel, it has many other regulatory roles, including in-
hibition of sodium transport through the epithelial
sodium channel, regulation of the outwardly rectifying
chloride channel, regulation of ATP channels, regulation
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of intracellular vesicle transport, acidification of intracel-
lular organelles, and inhibition of endogenous calcium-
activated chloride channels. CFTR is also involved in
bicarbonate–chloride exchange. There are several
hypotheses regarding how CFTR dysfunction leads to
the phenotypic disease. One of the major is the low-
volume hypothesis postulating that the loss of inhibition
of epithelial sodium channels, because of CFTR dysfunc-
tion, leads to excess sodium and water reabsorption,
resulting in dehydration of airway surface materials [5].
Newborn screening (NBS) offers the opportunity for
early diagnosis and improved outcome in patients with
CF [6–8]. There continues to be considerable variability
in structure of NBS programs [9]. NBS is done by the
measurement of immunoreactive trypsinogen (IRT) in
blood spots taken from newborn infants at day 3. Infants
who have a high IRT concentration (>99th centile)
undergo further assessment via a repeat IRT, 3 weeks
later (IRT/IRT2), or by analysis of the initial blood spot
for a specified group of CFTR mutations (IRT/DNA). A
sweat test must still be done to confirm the diagnosis in
infants with a positive NBS result. The sweat test re-
mains the most readily available and clinically useful way
of making the diagnosis of CF, provided it is done
according to strict guidelines, with pilocarpine ionto-
phoresis and a quantitative determination of chloride
concentration [1, 10, 11]. A diagnosis of CF can be made
in a patient with a positive NBS result and a sweat chlor-
ide concentrations greater than 60 mmol/L [1, 10].
The CF phenotype includes multi-organ involvement
with predominant severe respiratory disease, pancreatic
insufficiency (PI) and male infertility [5]. In the last years
an increasing number of patients have been described as
having CFTR-related disorder (CFTR-RD) [12]. These
cases are generally characterized by a later onset of
symptoms such as pancreatitis, [13] disseminated bronchi-
ectasis, congenital bilateral absence of vas deferens
(CBAVD) associated to normal or borderline sweat chlor-
ide concentrations (30–59 mmol/L for infants less than
6 months of age, 40–59 mmol/L for older individuals) and
two CF mutations with a different degree of CFTR protein
dysfunction [14]. Finally, the growing proportion of NBS
programs revealed a large number of infants having a
Cystic Fibrosis Screen Positive, Inconclusive Diagnosis
(CFSPID) in Europe or CFTR – related metabolic syn-
drome (CRMS) in the US including those infants with ele-
vated IRT levels, but with insufficient sweat chloride or
genetic data to support a diagnosis of CF [15, 16].
Nowadays the use of CFTR gene sequencing [17] led
to the detection of a number of variants for which it
lacks a clear genotype–phenotype correlation. Some of
these can reach a higher frequency only in certain popu-
lations, due to a founder effect in ethnic or geographical
isolates [18, 19].
S737F (c.2210C > T; p.Ser737Phe) is a CFTR missense
variant, located in exon 13 and characterized by a substi-
tution of serine with phenylalanine in position 737,
identified in 2004 in two Italian patients with pancreatic
sufficiency (PS) and pathological sweat chloride level
(SCL) in one case (Cl 71 mEq/l) and borderline in the
other (Cl 51 mEq/l) (submitted to http://www.genet.sick
kids.on.ca/cftr/app). Functional classification of this
variant still remains unknown and no data are available
in literature at the moment.
The aim of our study is to describe clinical features of
patients bearing such rare variant and to assess the re-
sidual function of CFTR protein on nasal epithelial cells
obtained by nasal brushing.
Methods
Patients population
We performed a retrospective analysis of clinical records
of all patients either homozygous or compound-
heterozygous for the S737F CFTR missense variant be-
tween 295 patients followed in the Cystic Fibrosis Centre
of Tuscany region (Italy). Demographic, clinical, genetic
and biochemical data regarding all enrolled patients
were extracted from local electronic health records. All
patients had given consent to the recording of their clin-
ical data and for their anonymous use for scientific
purposes, including descriptive studies. Furthermore, the
approval of Ethics Committee of University Federico II
of Naples was obtained for sampling of nasal epithelial
cells and for the functional analysis of novel mutations
in patients with CF.
Diagnostic tests and clinical data
All patients underwent NBS for CF by the analysis of
blood IRT at day 3 performed by using Auto-DELFIA
method until 2013 and by the GSP instrument from
2014 (Perkin-Elmer). Meconium lactase was detected by
glucose production after incubation of meconium with
lactose. The NBS algorithm is reproduced in Fig. 1.
From 2011 a pilot project was aimed to compare usual
diagnostic algorithm (IRT - meconium lactase - IRT2) to
a new protocol IRT-DNA.
We collected a new database including demographic data
and detailed clinical or genetic data at diagnosis, as follows:
gender, age at diagnosis, genotype and cause of diagnosis.
SCL, obtained according to guidelines by the Gibson
and Cooke method, [11, 20] were analyzed at diagnosis
and annually repeated in each patient with quantitative
pilocarpine iontophoresis. Furthermore sweat test was
performed in the same laboratory, thus ruling out the
lack of harmonization between different labs [21].
We defined CFSPID infants who are asymptomatic,
with hypertrypsinogenemia at birth and either: (1) 0 or 1
CFTR mutations, plus intermediate sweat chloride
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(30–59 mmol/L); or (2) 2 CFTR mutations, at least 1 of
which has unclear phenotypic consequences, plus a
normal sweat chloride (<30 mmol/L) [15].
Weight/Height pc or body mass index (BMI) pc were
evaluated in patients respectively under or beyond
2 years of age [22]. Last best forced expiratory volume in
the 1st second (FEV1), expressed as percentage of
predicted value for age, according to standardized refer-
ence equations for spirometry [23] were recorded for
patients aged over 6 years. Given the inter-individual
variability of FEV1 and the evolution of lung damage
with age, the patients were classified as “severe” or
“mild” according with Schluchter et al. criteria that takes
into account both the FEV1 value and age [24].
Endobronchial bacterial infections were detected by spu-
tum or throat swab cultures. Pseudomonas aeruginosa
(PA), Stenotrophomonas malthophilia (SM), Haemoph-
lus Influenzae (HI), Methicillin sensitive Staphylococcus
aureus (MSSA) or Methicillin resistant Staphylococcus
aureus (MRSA) chronic infection was defined following
modified Leeds criteria [25]. PS was defined on the basis
of at least two values of fecal pancreatic elastase higher
than 200 μg/g measured outside acute gastrointestinal
diseases [26]. Pancreatitis was defined according to the
report from the international study group of pediatric
pancreatitis [27]. Cystic fibrosis related diabetes mellitus
(CFRD) was diagnosed according to the American
Diabetes Association criteria [28]. CF-associated liver
disease (CFLD) was defined when imaging (ultrasound,
computed tomography, magnetic resonance) and
demonstrated hepatic parenchymal abnormalities and/or
portal hypertension (esophageal varices, portal-systemic
collaterals, splenomegaly) in the absence of other causes
[29]. Complications such as allergic bronchopulmonary
aspergillosis (ABPA), meconium ileus (MI) or distal in-
testinal obstruction syndrome (DIOS), nasal polyposis,
hemoptysis, and pneumothorax were registered.
Genetic analysis
According to European recommendations, [30] molecu-
lar analysis was performed testing a panel of the most
frequent CFTR mutations followed by the search of the
most frequent CFTR rearrangements [31] and sequen-
cing of the whole coding regions of CFTR [14] once one
or both mutations had not been identified. Before 2011
we performed genetic analysis in all infants with a
pathological sweat chloride in order to confirm CF diag-
nosis, while since 2011 it has become part of the screen-
ing program (IRT-DNA) (Fig. 1).
Nasal brushing
In order to assess the residual function of CFTR protein,
we performed a nasal brushing in cooperating patients
bearing S737F CFTR variant and compared the results
with those of CF patients with other genotypes followed
in the pediatric Cystic Fibrosis Centre of Campania re-
gion (Italy). The informed consent was required to the
patients (legal guardian for minors) before sampling,
after a complete description of the aims of the study. All
subjects underwent a complete ear-nose-throat
Fig. 1 The newborn screening algorithm used at the CF Centre of Florence, Italy
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evaluation. To test the activity of the CFTR protein, we
used the halide-sensitive fluorescent system. Details are
provided in a previous paper of our group [32, 33].
Results
Genotype, clinical data and clinical course
Nine subjects carrying at least one S737F were identified
after gene sequencing (detection rate 98%): 8 were com-
pound heterozygous for the S737F and one class I–II
mutation (mean age: 8,9 years, range 0,5–15,8 years),
while one patient (8,4 years) was homozygous for the
S737F (Table 1).
No detection of complex alleles has been found. 7/9
patients were diagnosed by NBS and were considered
CFSPID infants having a borderline SCL and one CFTR
causing mutation. In the remaining two cases (resulted
negative at NBS) diagnosis was performed at the age of
10 months and 20 months respectively, after an episode
of dehydration with hypochloremic metabolic alkalosis
during the summer needing hospitalization. At diagno-
sis, one case had SCL in the pathological range (Cl:
71 mEq/L) while in 8/9 cases SCL was in the intermedi-
ate range for age (Cl 30–59 mEq/L for infants under the
age of 6 months; Cl 40–59 mEq/L for patients over
6 months) (Table 1) [10]. During follow up SCL, annu-
ally o semesterly evaluated in each patient, gradually in-
creased with age: the last SCL was pathological for age
(range 60–121 mEq/L) in 8/9 patients (defining a CF
diagnosis), while in only one case it remains unmodified
in borderline range (Table 2). The mean age at diagnosis
of CF was 1,5 years (range 0,2–3,8).
Lung function tests were available in 6 cooperating pa-
tients: according to Schluchter et al. criteria, [24] all
patients were classified as “mild” for age (Table 2).
After a mean follow up of 8,6 years (range 0,5–15,8),
all patients were PS and in good nutritional status (with
five of them having a BMI ≥ 95° pc). None of them had
presented pancreatitis, CFLD, CFRD or other complica-
tions. Sputum or throat swab cultures revealed chronic
infection by MSSA in 6/9 cases and occasional infection
of PA, SM, or HI in the other cases (Table 2).
Respiratory exacerbations, requiring oral antibiotics
prescription were uncommon in all patients over the
time (only the patient n.5 required a cycle of oral cipro-
floxacin and aerosol therapy in order to eradicate PA
infection). Chest High Resolution Computed Tomog-
raphy scan showed the absence of bronchiectasis in
patients n. 5 and n. 6. In order to exclude CBAVD pres-
ence, we proposed the analysis of spermiograms for the
two males adolescents patients but the parents refused.
Nasal brushing
As shown in Fig. 2, we analyzed the CFTR gating activity
on nasal epithelial cells obtained from several CF pa-
tients and carriers. In particular, we studied: i) three
patients with CF of which one was homozygous for the
F508del mutation (case #1), another was compound het-
erozygous for the N1303 K and the [R74;V201 M;D1270]
complex allele (case #2) and the third was compound
heterozygous for the N1303 K and the 711 + 1G > T mu-
tations (case #3) (the phenotypes are showed in Table 3)
[32]. They showed an activity of 6,2%, 9,8% and 5,2%,
respectively; ii) a CF patient compound heterozygous for
the W1282X and D1152H mutation [32] (Table 3). He
had an activity of 20.3% (case #4); iii) two patients
compound heterozygous for the S737F variant with the
W1282X mutation (case #5) and with the DelE22_24 (case
#6). Such cases showed an activity of 15.6% and 12.7%, re-
spectively (the phenotypes are showed in Table 2 and in
Table 3, cases # 5 and 6); iv) two carrier subjects, hetero-
zygous for the F508del mutation (case #7) and for the
G542X mutation (case #8); they had an activity of 40.7
and 76,8% (Table 3).
Discussion
We described the first cohort of patients bearing the
S737F CFTR missense variant and evaluated the residual
function of CFTR protein on nasal epithelial cells
Table 1 demographic data of the enrolled patients
Patient Gender Age at diagnosis (months) Cause of diagnosis Second mutation SCL at diagnosis IRTa (ng/ml)
1 M 1 NBS F508del 46 74
2 M 20 Hypochloremic Alkalosis S737F 45 31
3 M 1 NBS F508del 35 76
4 F 1 NBS 541delC 48 108
5 M 10 Hypochloremic Alkalosis 22,23,24 del 71 37
6 M 1 NBS W1282X 51 79
7 F 1 NBS F508del 52 100
8 F 1 NBS F508del 49 76
9 M 1 NBS F508del 51 76
SCL sweat chloride level, IRT blood immunoreactive trypsinogen, NBS newborn screening
aIRT is elevated for values >99th centile, variable every 3–4 months from 50 to 64 ng/ml
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obtained by nasal brushing in comparison to patients
with other genotypes. Our results show that S737F is as-
sociated to hypochloremic alkalosis in childhood, mild
CF phenotype in teenage years and a residual function
of CFTR protein. In fact, despite 7 patients resulted
positive to NBS, the other two were diagnosed by a sin-
gle episode of dehydration with hypochloremic meta-
bolic alkalosis. Furthermore, all 9 patients presented PS
and good nutritional status, all had normal respiratory
function for age and none of them developed complica-
tions during follow up. Only one patient presented an
occasional isolation of P. aeruginosa that eradicated after
antibiotic therapy. Nevertheless the mean age and the
follow up of our patients are too low to exclude a severe
course of the pulmonary disease in adulthood or the de-
velopment of pancreatic insufficiency.
It is known that some mutations are more frequent in
specific regions or ethnic groups [18, 19]. Interestingly
all the families of the patients were residing in the
Tuscany region for at least two generations. Our data
confirm the need to investigate the regional origin of
each patient with suspected CF in order to reduce the
residual risk that a couple negative for the test will have
an affected child [19]. Furthermore is also necessary to
adapt neonatal screening panels based on the frequency
of mutations in each region.
The management of children with an inconclusive
diagnosis following NBS has been recently discussed [15,
16]. In some cases the sweat chloride result may be in
intermediate range or CFTR gene changes may be rec-
ognized, the phenotypic consequences of which are
unclear. According to Munck et al. and Ooi et al., in our
cohort we repeated annually or semesterly the sweat test
and during follow up 6/7 CFSPID infants moved to a CF
diagnosis given that sweat test moved from an inter-
mediate to a CF-confirmatory result [6, 33, 34]. Unlike
Ooi et al. [33] sweat chloride increased to abnormal
levels at a slightly lower mean age (21,3 months vs
17 months).
The sensitivity of NBS for CF diagnosis depends on
the IRT cut off as well as the population screened as a
result of differences in the genotypic distribution for
CF in the population, with estimates of false negative
results ranging from 1.7–5.4% of children with CF [35,
36]. Delay in diagnosis of CF and, hence, delay in treat-
ment is associated with deleterious outcomes including
nutritional and growth concerns, a higher rate of com-
plications, increased stress to the families, and the
potential for poorer pulmonary outcomes [37–39].
Nevertheless, the effect of age of diagnosis on survival
with CF is moot given that it is not the only factor af-
fecting the survival [36, 40–42]. In a 30 year retrospect-
ive review of survival with CF from two regions in Italy
including diagnosis by symptoms and NBS, Assael et al.
reported that patients diagnosed after 5 years of age
appeared to have a survival advantage over those
Table 2 Clinical data of the enrolled patients
Patient Age (years) PS FEV1 Sputum pathogens Pc BMI (°) SCL at enrolment (mEq/l) Follow up (years)
1 9,5 Yes NA Hi, Mssa 95 46 9,5
2 8,4 Yes 99 Mssa >95 98 6,6
3 9,7 Yes 101 Hi 95 78 9,7
4 8,8 Yes 96 Mssa, Sm 75–85 94 8,8
5 15,7 Yes 99 Pa 75–85 89 14.9
6 15,8 Yes 108 Mssa 50–75 121 15,8
7 10,7 Yes 114 Mssa > 95 60 10,7
8 0,5 Yes NA Mssa >95a 68 0,5
9 1,5 Yes NA Hi 90a 67 1,5
PS pancreatic sufficiency, FEV1 forced expiratory volume in the 1st second, SCL sweat chloride level, NA not available, Hi Haemophilus Influenzae, Mssa Methicillin
sensitive Staphylococcus aureus, Sm Stenotrophomonas malthophilia, Pa Pseudomonas Aeruginosa
aWeight/Height pc were evaluated in patients under 2 years of age
Fig. 2 CFTR gating activity on nasal epithelial cells obtained from CF
patients and carriers with different genotypes. 1: F508del/F508del;
2: F508del/[R74;V201 M;D1270]; 3: N1303 K/711 + 1G > T; 4: W1282X/
D1152H; 5: S737F/W1282X; 6: S737F/DelE22_24; 7: F508del
(heterozygous); 8: G542X (heterozygous)
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diagnosed under 1 year of age without a significant
effect of NBS on survival [40].
In our cohort two patients (cases 2 and 5) resulted
negative at NBS and were diagnosed at the age of
10 months and 20 months after an episode of dehydra-
tion with hypochloremic metabolic alkalosis during the
summer. This is a relatively common and sometimes
dangerous manifestation of CF in infancy; the possibility
of CF diagnosis should be considered in any infant with
this metabolic disorder even if resulted negative at new-
born screening. In order to prevent these events we have
included S737F mutation in cystic fibrosis neonatal
panels screening and we suggest to look for S737F in
subjects of Tuscany region origin with symptoms
compatible with cystic fibrosis.
The analysis of CFTR gating activity on ENC confirms
that such analysis may help to define the residual activity
of the mutated protein and seems to correlate with the
severity of the CF phenotype. In fact, the three patients
with severe CF and compound heterozygous for two
CFTR severe mutations (cases 1 to 3) show a very low
residual CFTR activity (i.e., < 10%); the two heterozy-
gous subjects show an activity between 40 and 80%, and
the patient with mild CF, compound heterozygous for
the W1282X and the mild D1152H mutation [43] had
an activity in the range 10 to 20%. The two cooperating
patients bearing the S737F mutation show a residual
CFTR activity of 12.7 and 15.6%, according to a mild CF
clinical expression (that seems to be associated to re-
sidual activity ranging from 10 to 20%).
Conclusions
S737F seems to be a CFTR mutation, typical of patients
originally from the Tuscany region, associated to a re-
sidual activity of the CFTR protein assessed in nasal
epithelial cells. We have included this mutation in cystic
fibrosis neonatal panels screening in order to prevent
dangerous episodes of dehydration with hypochloremic
metabolic alkalosis.
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